Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: DRUG: Bevacizumab and eribulin
Sponsor: Consorzio Oncotech
Collaborators: Clinical Research Technology S.r.l.